Veterans Gain Access to EsoGuard Test for Esophageal Cancer Screening Through VA Contract

Expanding Access to Esophageal Cancer Screening for Veterans

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., has recently secured a significant contract with the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test. This development enhances access to essential precancer testing for over nine million enrolled veterans annually. The contract, part of the VA Federal Supply Schedule, features pre-negotiated pricing based on Medicare payment rates established by the Centers for Medicare & Medicaid Services (CMS). This streamlined procurement process allows VA hospitals and healthcare facilities nationwide to more easily access EsoGuard, which is crucial for early detection of esophageal precancer in at-risk populations.

Shaun O’Neil, President and COO of Lucid Diagnostics, highlights the importance of this partnership, expressing pride in the expanded availability of EsoGuard for veterans. The test significantly benefits patients suffering from gastroesophageal reflux disease (GERD), a condition that increases the risk of developing esophageal precancer and cancer. EsoGuard stands out as the first commercially available tool specifically designed for early detection, emphasizing Lucid’s commitment to preventing cancer and reducing mortality rates among vulnerable populations. O'Neil’s statements underscore the company’s dedication to integrating EsoGuard into standard clinical practices, thereby enhancing patient outcomes through proactive screening measures.

The EsoGuard test utilizes samples collected via the noninvasive EsoCheck® Esophageal Cell Collection Device, which simplifies the testing process and makes it more accessible for patients. By targeting veterans, Lucid Diagnostics aims to address a critical gap in healthcare services for those at heightened risk due to their medical history. This contract not only represents a significant step forward in the fight against esophageal cancer but also demonstrates Lucid’s strategic focus on leveraging partnerships to expand the reach of its innovative diagnostic solutions.

In addition to this contract, Lucid Diagnostics continues to emphasize the clinical evidence supporting the EsoGuard test, reinforcing its validity and effectiveness in identifying precancerous conditions. The company aims to work closely with various healthcare systems to integrate this testing method into routine clinical practice, ensuring that at-risk populations receive timely and appropriate care. For more information about their offerings, interested parties are encouraged to visit Lucid Diagnostics' official website or that of its parent company, PAVmed Inc.